6-amino-5-((1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-(4-methylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide,
ensartinib,
X-396,
X-396,
1365267-27-1,
X-376,
UNII-7DR7JMB8BH,
7DR7JMB8BH,
CHEMBL2376648,
(R)-6-Amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-(4-methylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide,
GTPL8959,
SCHEMBL15131466,
BCP07190,
EX-A2227,
BDBM50432894,
ZINC96258164,
AKOS030528612,
CS-6077,
DB13104,
Example 18 [WO2012048259],
3-Pyridazinecarboxamide, 6-amino-5-((1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((4-methyl-1-piperazinyl)carbonyl)phenyl)-,
BC600712,
HY-16590,
X376,
X 396,
X-376; X-396,
6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-(4-methylpiperazine-1-carbonyl)phenyl]pyridazine-3-carboxamide,
ensartinib,
ALK inhibitors (cancer),
D0L9PA,
ALK inhibitors (cancer), Xcovery,
X396,
X-276,
X-353,
Anaplastic lymphoma kinase inhibitors (cancer), Xcovery,
N/A,